| 1 | Department of Defence (PDF 19284 KB)
1.1 Supplementary to submission 1 (PDF 10462 KB)
1.2 Supplementary to submission 1 (PDF 306 KB) |
| 3a6e32a8-4d3b-451f-9f4b-ca978454d94c~613631|c51881e9-3301-4f30-b5dc-af42dafa2d3e~613631|4ff841f4-a749-41bf-80d1-a170e00fa079~613631 |
| 2 | Department of Veterans' Affairs (PDF 482 KB) |
| db7f254b-5392-41ad-ab4b-b85ef59ba8bf~658004 |
| 3 | Department of Health (PDF 1794 KB) |
| 774fcfb9-ca0d-497f-91e3-a90e96a64b05~658013 |
| 4 | Repatriation Medical Authority (PDF 640 KB) Attachment 1 (PDF 526 KB) Attachment 2 (PDF 133 KB) Attachment 3 (PDF 7175 KB) Attachment 4 (PDF 1595 KB) Attachment 5 (PDF 756 KB) |
| 59531b19-bb51-4a8b-aabd-fa3f65cb6349~657926|825a0853-5ed7-47f8-97a9-6c621f330886~657926|4b4c47fd-9664-4f19-98c4-d3f117e872ef~657926|994b8070-6f02-451c-b8c6-506e9e8e9fdd~657926|2e6309cc-ae7d-4c5c-a349-a0aba968d455~657926|21f7cf8a-3cee-4f7e-8990-85f58cdf0c2c~657926 |
| 5 | Asia Pacific Leaders Malaria Alliance (PDF 162 KB) |
| 61db4e62-7f9c-4652-938c-a3bb35e635c8~657902 |
| 6 | Australasian Society for Infectious Diseases (ASID) Inc. (PDF 101 KB) |
| 291bc213-2591-48d0-bcb5-a2485c2b9ea2~613267 |
| 7 | Australasian College of Tropical Medicine (PDF 213 KB) |
| 87abe1f1-aa4c-47f8-bcff-9b04980de32b~657863 |
| 8 | GlaxoSmithKline Australia Pty Ltd (PDF 202 KB)
8.1 Supplementary to submission 8 (PDF 231 KB) |
| 4e75d6a0-b22b-4a9e-bc85-a42d4de9b30b~657956|14825040-70fa-4689-a45a-86e46583304d~657956 |
| 9 | 60 Degrees Pharmaceuticals LLC (PDF 174 KB) Attachment 1 (PDF 11949 KB)
9.1 Supplementary to submission 9 (PDF 317 KB)
9.2 Supplementary to submission 9 (PDF 3503 KB)
9.3 Supplementary to submission 9 (PDF 1672 KB) |
| 992561fb-4d83-4a64-b1c4-ebe74c2f313b~658014|6c9b4514-0d60-4c5b-88f5-0bfe9365c8e9~658014|459c69bc-3022-4c43-b370-ab8383918ba7~658014|8f640b53-7d14-4554-bb08-8c29759f3d9c~658014|44ad68f9-97f8-4c92-b86e-ff8ccf05e1bf~658014 |
| 10 | Medicines for Malaria Venture (PDF 154 KB) Attachment 1 (PDF 197 KB) Attachment 2 (PDF 6335 KB) Attachment 3 (PDF 103 KB) |
| acb6ddb0-5c6a-44fc-8db5-0607ceeab6e5~658012|59651f29-2431-439a-9828-d636ba8a131f~658012|275fddd3-0883-408b-ac8f-3c81b01a9696~658012|e366402e-eeee-4156-a83c-b6fb3e501764~658012 |
| 11 | Biocelect Pty Ltd (PDF 129 KB) |
| 2c1c6686-7420-4e55-bc17-bf90dd588d12~657948 |
| 12 | Roche Products Pty Ltd (PDF 449 KB) |
| 1fe598a1-1b7f-4a41-bec3-94c71bb3a95e~657858 |
| 13 | Prof G Dennis Shanks (PDF 79 KB) |
| 59a93c17-6a4a-4d04-b797-01e556010ce8~613729 |
| 14 | Professor James McCarthy (PDF 110 KB) |
| 9046f7c9-d4ec-414e-b85a-450bb24f6808~612764 |
| 15 | Associate Professor Harin Karunajeewa (PDF 154 KB) |
| c7716a74-6f16-442f-822a-4689f23ce633~613687 |
| 16 | Australian Quinoline Veterans and Families Association (PDF 1006 KB)
16.1 Supplementary to submission 16 (PDF 746 KB)
16.2 Supplementary to submission 16 (PDF 764 KB)
16.3 Supplementary to submission 16 (PDF 6924 KB)
16.4 Supplementary to submission 16 (PDF 2302 KB)
16.5 Supplementary to submission 16 (PDF 1017 KB)
16.6 Supplementary to submission 16 (PDF 13888 KB)
16.7 Supplementary to submission 16 (PDF 1447 KB)
16.8 Supplementary to submission 16 (PDF 699 KB)
16.9 Supplementary to submission 16 (PDF 4197 KB)
Response by Mark Reid to Supplementary Submission 16.7 (PDF 428 KB)
Response by Dr Geoff Dow to Supplementary Submission 16.7 (PDF 13913 KB)
Response by Dr Bryan Smith to Supplementary Submission 16.7 (PDF 196 KB)
Response by Mark Reid to Supplementary Submission 16.8 (PDF 352 KB)
Response by Professor Brown and Professor Quail to Supplementary Submission 16.9 (PDF 77 KB) |
| 205f1db1-795e-47fb-ac4a-964274628890~612955|1fe12cdc-a35d-4ffd-9fec-4e530d1c0ccf~612955|dadb5dc9-ef7f-4227-a3b8-f057afe1d32e~612955|a8df2079-eb79-4fb8-aff4-3a677801d18d~612955|ecd39866-0d9a-49fe-a990-4d4d2b6c4a11~612955|821ae11f-3101-4650-8b61-04b55e04269b~612955|e7b4660c-66c0-40bd-be7b-4efc3b005176~612955|6d3f854f-314e-4fbb-abad-04c932379cd6~612955|ac53afa9-dee2-4e77-aa20-5cc7bd840fd7~612955|a29052d2-f62d-4de3-bc5b-de419b8693e3~612955|d17cb210-e4a8-4638-b2ee-0d156a83f814~612955|acad9d30-67de-4814-ac59-09230b72563c~612955|a81c9b4b-74f7-496e-9955-c960b02a957c~612955|76c45ac0-5fdf-49f6-8f32-3f194e05c0ef~612955|67f1610b-00ca-4023-9d3d-f58c3d3c5e0e~612955 |
| 17 | The Quinism Foundation (PDF 1224 KB)
17.1 Supplementary to submission 17 (PDF 565 KB) |
| 5820d0d7-64d9-425d-816c-27a83390582d~657923|3203b76b-27e9-456e-a50e-fac5e5c8ccab~657923 |
| 18 | LTGEN John Caligari (Rtd) (PDF 77 KB) |
| 44c9d6c9-cc7a-4092-a850-c91b30926d6d~657989 |
| 19 | Confidential |
| |
| 20 | Mr Luke Kain (PDF 61 KB) |
| 68b6e0ad-1195-4f96-8943-4f731f8c060a~613637 |